Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
Outset Medical is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, a compact console that integrates water purification, on-demand dialysate production and cloud connectivity for use in hospitals, clinics and homes.
The company emphasizes ease of use, reduced infrastructure needs and rich data analytics through platforms like TabloHub, MyTablo and TabloDash to improve operational efficiency and device uptime. As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was approximately $334.7 million, and 18,311,626 shares were outstanding as of February 10, 2026.
Outset operates in a competitive dialysis market against large players such as Fresenius and DaVita, relies on a sizable global patent portfolio expiring between June 2027 and April 2042, and manufactures primarily in Mexico under ISO 13485 standards. Tablo is regulated as a Class II device with multiple 510(k) clearances, including a next‑generation platform cleared in January 2026, and prior FDA inspection and warning letter issues have been closed. Revenue is heavily influenced by U.S. reimbursement frameworks, notably the ESRD Prospective Payment System base rate of $281.71 per treatment for 2026 and evolving Medicare payment models and health‑reform policies.
Outset Medical reported full-year 2025 revenue of $119.5 million, up 5% from 2024, with gross margin improving to 39.1% from 33.9%. Net loss narrowed to $81.7 million versus $128.0 million a year earlier as operating expenses fell significantly.
Recurring revenue from Tablo consumables and services grew 6% to $88.7 million, and total cash, including investments, reached $172.8 million at year-end. The company also received FDA clearance for its next-generation Tablo platform. For 2026, it guides revenue to $125–$130 million and expects non-GAAP gross margin in the low to mid-40% range.
Bank of America Corporation filed a Schedule 13G reporting a beneficial ownership position in Outset Medical, Inc. common stock. The firm reports holding 950,558 shares, representing 5.2% of the outstanding common stock, based on 18,153,090 shares outstanding as of November 6, 2025.
All voting and dispositive power over these shares is described as shared, with no sole voting or dispositive authority. The filing is made on behalf of Bank of America and several wholly owned subsidiaries, and it states the shares were acquired and are held in the ordinary course of business, not to influence control of Outset Medical.
Outset Medical, Inc. reported that the U.S. Food and Drug Administration has granted 510(k) clearance for its next-generation Tablo hemodialysis platform. This clearance allows the updated system to be marketed in the United States under its cleared indications.
The company stated that it expects to begin shipping the next-generation Tablo platform to customers in the second quarter of 2026. Outset highlighted that future performance and impact of the product, as well as the timing of enhancements and new features, remain subject to various risks and uncertainties described in its SEC filings.
Outset Medical, Inc. executive Marc Nash reported two sales of company common stock. On January 20, 2026, he sold 5,375 shares at $5.12 per share, followed by a sale of 980 shares at $4.98 per share on January 21, 2026, all held directly.
The footnote explains these 6,355 shares were sold to cover partial tax withholding obligations tied to the vesting of 14,839 RSU-based shares granted on June 10, 2025, and that the transactions did not represent discretionary trades by Nash. After these sales, he directly owned 41,805 shares of Outset Medical common stock.
Outset Medical, Inc.'s General Counsel, John L. Brottem, reported automatic sales of company common stock to cover tax withholding on recently vested equity awards. On January 20, 2026, he sold 9,314 shares of common stock at $5.12 per share, leaving him with 36,957 shares beneficially owned. On January 21, 2026, he sold an additional 1,180 shares at $5.01 per share, resulting in 35,777 shares beneficially owned afterward.
The filing explains that these 10,494 shares were the required number sold to partially cover tax withholding tied to the vesting of 17,997 shares of common stock underlying RSUs granted to him on June 10, 2025. The sales were executed as a “sell to cover” transaction for tax purposes and are described as not discretionary trades by the reporting person.
Outset Medical, Inc. insider filing shows tax-related share sales by Chair and CEO Leslie Trigg. On January 20, 2026, Trigg sold 11,794 shares of common stock at
According to the footnote, these transactions were the required number of shares sold to cover partial tax withholding obligations tied to the vesting of 32,552 RSU-based shares granted on
Outset Medical insider plans additional stock sale under Rule 144. The filing indicates that Leslie Trigg intends to sell 2,120 shares of Outset Medical common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of
The notice also reports prior sales over the past three months, including 916 shares on 11/17/2025, 1,795 shares on 01/07/2026, and 11,794 shares on 01/20/2026, for gross proceeds of
Omnicell stockholder Marc Nash filed a notice of proposed sale under Rule 144. He plans to sell 980 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/21/2026, with an aggregate market value of $4,876.11. The shares are listed on NASDAQ, and the issuer had 18,153,090 shares outstanding at the time stated.
The securities to be sold were acquired on 01/17/2026 via settlement of 14,839 vested restricted stock units as equity compensation for services rendered. Over the prior three months, Nash sold additional common shares, including 247 shares for $1,136.20, 108 shares for $461.16, and 5,375 shares for $27,520.00. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about the issuer.
OM insider John Brottem has filed a Form 144 indicating an intention to sell 1,180 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ around 01/21/2026. The aggregate market value of these shares is listed as $5,913.82, compared with 18,153,090 shares of common stock outstanding. The shares to be sold stem from equity compensation: on 01/17/2026, Brottem acquired 17,997 shares via settlement of vested restricted stock units as payment for services.
Over the prior three months, Brottem has sold additional OM common stock, including 388 shares for $1,784.80 on 11/17/2025, 244 shares for $956.48 on 01/07/2026, and 9,314 shares for $47,682.76 on 01/20/2026. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.